Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

scientific article published on 27 October 2015

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1015421309
P356DOI10.1007/S40262-015-0337-4
P2888exact matchhttps://scigraph.springernature.com/pub.10.1007/s40262-015-0337-4
P698PubMed publication ID26507720
P5875ResearchGate publication ID283306453

P2093author name stringHong Zhang
Yimin Cui
Kenichi Yoshikawa
Xia Zhao
Reiner Frey
Sigrun Unger
Hartmut Blode
Yukun Wang
Corina Becker
Zining Wang
P2860cites workNO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialQ24656131
Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparationsQ30449094
Riociguat for the treatment of chronic thromboembolic pulmonary hypertensionQ33163081
Riociguat for the treatment of pulmonary arterial hypertensionQ33163083
Drug interactions with tobacco smoking. An updateQ33700123
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.Q34786286
Polymorphism of human cytochrome P450 enzymes and its clinical impactQ37514326
Updated treatment algorithm of pulmonary arterial hypertension.Q38172728
Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR.Q44457201
Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placentaQ45078610
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteersQ46562534
Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failureQ46793768
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.Q52422731
Pulmonary Arterial HypertensionQ56388760
P433issue5
P921main subjectriociguatQ2154494
P304page(s)615-624
P577publication date2015-10-27
P1433published inClinical PharmacokineticsQ5133788
P1476titlePharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study
P478volume55

Reverse relations

Q47584698Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguatcites workP2860

Search more.